SAFC Commercial, the custom manufacturing services business
), has clinched commercial sales and licensing contracts from two
premier Asian biopharmaceutical companies. The agreement is for
the sale and licensing of CHOZN, the off-the-shelf cell line
Bioproduction platform, to the Asian biopharmaceutical
developers. This strengthens SAFC's biopharmaceutical market
presence in Asia.
The CHOZN Platform is featured as a prime component of
customers' global biotherapeutic commercialization strategy in
these contracts. The CHOZN Platform comprises the CHOZN GS-/- CHO
cell line and an optimized set of cGMP-produced, chemically
defined (CD) media and feeds specifically geared for the cell
line to maximize the production of monoclonal antibodies and
The CHOZN GS (-/-) platform provides a stable cell line that
accelerates selection and scale-up of high-producing clones for
the production of recombinant protein drugs by conserving weeks
of development. CHOZN, along with Sigma-Aldrich's CompoZr Zinc
Finger Nuclease (ZFN) technology, provides a gateway from
development through commercialization.
SAFC also provides worldwide user support along with cell
line, media and feed. SAFC works with customers on building
protocols from transfection through to scale-up in bioreactors,
as well as providing comprehensive cell line safety testing and
development history packages. Moreover, the CD media and
feed system allows for tunable product quality.
Sigma-Aldrich expects to widen its foothold in Asia based on
its ability to speed up upstream development timelines to
favorably impact the potential profitability of biotherapeutic
Sigma-Aldrich currently maintains a Zacks Rank #4 (Sell).
Other companies in the specialty chemical space with favorable
Zacks Rank are
OM Group Inc.
American Vanguard Corp.
). While OM Group and American Vanguard hold a Zacks Rank #1
(Strong Buy), Ferro Corp retains a Zacks Rank #2 (Buy).
AMER VANGUARD (AVD): Free Stock Analysis
FERRO CORP (FOE): Free Stock Analysis Report
OM GROUP INC (OMG): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.